News & Publications - Page 2 of 13

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

  • KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline

  • KemPharm Reports First Quarter 2022 Financial Results and Corporate Updates

  • KemPharm to Present at Multiple Upcoming Investor Conferences

  • KemPharm Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH)

  • KemPharm to Report First Quarter 2022 Financial Results

  • KemPharm Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)

  • KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates

  • KemPharm to Participate in Maxim’s 2022 Virtual Growth Conference

  • KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial

  • KemPharm Earns $1.975 Million Fee from Corium Following FDA Approval of the Corium Product ADLARITY® (donepezil transdermal system)

  • KemPharm to Report Fourth Quarter and Full-Year 2021 Results

  • KemPharm Completes KP1077 Pre-IND Meeting Process with FDA